Eli Lilly and Company launched Humalog mix 75/25 kwikpen and Humalog Junior kwikpen for diabetic ketoacidosis treatment market

 

Diabetic Ketoacidosis Treatment Market

The growing prevalence of diabetes and diabetic ketoacidosis is fostering the growth of the diabetic ketoacidosis treatment market. According to the U.S National Library of Health, the frequency of diabetic ketoacidosis in adults with type1 diabetes is high, and approximately one-third of the adults have severe conditions such as diabetes type-1 and diabetic ketoacidosis. Additionally, healthcare providers are focused on spreading awareness regarding diabetes type 1 and diabetic ketoacidosis which is again fostering the growth of the diabetic ketoacidosis treatment market. For instance, in April 2020, Diabetes UK, a healthcare and research charity association in England, stated that the National Health Services should be kept open for emergency conditions such as diabetic ketoacidosis as they may lead to life-threatening situation.

In August 2020, Eli Lilly and Company (United States) added two non-branded insulin products Humalog mix 75/25 kwikpen and Humalog Junior kwikpen at a cost-effective range to make treatment of type-1 diabetes and its complications such as diabetic ketoacidosis more affordable.

In 2019, Medtronic, a medical device company in Ireland, merged with Nova Nordisk, a pharmaceutical company in Denmark. The aim of this partnership is to develop solutions for diabetes and diabetic ketoacidosis by combining insulin dosage data from future Novo Nordisk and smart insulin pens by Medtronic’s Continuous Glucose Monitoring (CGM) devices.

North America is expected to lead the global diabetic ketoacidosis treatment market and this is accredited to the increasing focus of the pharmaceutical industry to focus increase the availability of supportive treatment for diabetic ketoacidosis. For instance, in June 2020, Lexicon Pharmaceutical Inc. announced the use of Zynquista (sotagliflozin) to balance the risk of diabetic ketoacidosis in adults with type-1 diabetes at the Virtual 80th American Diabetic Association scientific session.

Diabetic ketoacidosis is often a dangerous complication of diabetes, which occurs when your body creates unusually high levels of acid known as ketones in the bloodstream. Early detection of this condition may help to avoid long-term complications which are far worse than the immediate discomfort of low glucose levels. The following symptoms may indicate that diabetic ketoacidosis may be occurring. Diabetic ketoacidosis are formed when fat is broken down in the liver instead of being converted into energy. There are two main types of this condition, one is marked by breath odor and the other by unusual nausea or vomiting. Breath odor that is fruity-scented breath has been identified as one of the first warning signs of ketoacidosis in the bloodstream.


Comments

Popular posts from this blog

Fitness Equipment Market is doing warm-ups to pull growth-rich opportunities from the growing obesity rates accompanied by the sedentary lifestyles

The market for ureteral stents would benefit from the rising prevalence of urological diseases

Increased Prevalence of Chronic Diseases and Stem Cell Therapy R&D to Drive Stem Cell Assay Market Growth